Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 408-410

  Takeda, Tomohiro ^a,b   Sakurai, Yoshihiko ^a,c   Tatsumi, Kohei ^a   Kato, Junko ^a   Kasuda, Shogo ^a   Yoshioka, Akira ^a   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Uda General Hospital   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN; PROTEOHEPARAN SULFATE; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; TNFSF13 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD SAMPLING; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; LETTER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; INFANT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UP-REGULATION; YOUNG ADULT;

EID: 62449266350     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-08-0543     Document Type: Letter

References (17)

1. Qian J, Borovok M, Bi L, et al. Inhibitor antibody development and T cell response to human factor VIII in murine haemophilia A. Thromb Haemost 1999; 81: 240-244.
2. Lavigne-Lissalde G, Schved JF, Granier C, et al. Anti-factor VIII antibodies; a 2005 update. Thromb Haemost 2005; 94: 760-769.
3. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-475.
4. Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
5. Bischof D, Elsawa SF, Mantchev G, et al. Selective activation of TACI by syndecan-2. Blood 2006; 107: 3235-3242.
6. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134-139.
7. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
8. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-798.
9. Bosello S, Pers JO, Rochas C, et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007; 20: 1-8.
10. Groom J, Kalled SL, Cutler AH. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002: 109: 59-68.
11. Migita K, Abiru S, MaedaY, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68: 586-591.
12. Hausl C, Maier E, Schwarz HP, et al. Long-term persistence of anti-factor VIII antibody-secreting cells in haemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-845.
13. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101: 3903-3908.
14. Malhias M, Khair K, Hann T, et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004;125:366-368.
15. Carcao M, St Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
16. Collins PW. Treatment of acquired haemophilia A. J Thromb Haemost 2007; 5: 893-900.
17. Cohen SB. Updates from B cell trials: efficacy. J Rheumatol (Suppl) 2006; 77: 12-17.